Home/Filings/4/0001193125-26-002512
4//SEC Filing

Russo Rene 4

Accession 0001193125-26-002512

CIK 0001840233other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 4:30 PM ET

Size

10.0 KB

Accession

0001193125-26-002512

Insider Transaction Report

Form 4
Period: 2025-12-31
Russo Rene
DirectorPRESIDENT AND CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-01+44,250325,422 total
  • Award

    Stock Option (right to buy)

    2025-12-31+1,500,2581,500,258 total
    Exercise: $0.84Exp: 2035-10-07Common Stock (1,500,258 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-0144,25088,500 total
    Common Stock (44,250 underlying)
Footnotes (5)
  • [F1]Restricted stock units ("RSUs") convert to stock on a one-for-one basis.
  • [F2]On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 3 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met.
  • [F3]The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025.
  • [F4]This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
  • [F5]These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.

Documents

1 file

Issuer

Xilio Therapeutics, Inc.

CIK 0001840233

Entity typeother

Related Parties

1
  • filerCIK 0001722066

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:30 PM ET
Size
10.0 KB